If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
TRULICITY® (dulaglutide): Gastroparesis
Trulicity (dulaglutide) has not been studied in patients with severe or preexisting gastroparesis.
Dulaglutide slows gastric emptying.1
Use of dulaglutide may be associated with GI adverse reactions, sometimes severe.1
Dulaglutide has not been studied in patients with severe GI disease, including severe or preexisting gastroparesis, and is therefore not recommended in these patients.1
Enclosed Prescribing Information
TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
GI = gastrointestinal
Date of Last Review: July 10, 2018
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
